OnDemand: October 2025 Grand Rounds - Nothing Is More Expensive than a Missed Opportunity

This talk is about the ability of new GLP-1 Receptor targeting to transform the global chronic disease epidemic and the barriers to uptake of this biologic breakthrough in the current medical establishment. Technology has the ability to transform medical care in this area. Will we move bravely forward? Or will we get stuck in the inertia of current care pathways?

Describe the mechanisms of action and current evidence supporting GLP-1 receptor–targeted therapies in the management of chronic disease.

Analyze barriers to the adoption of GLP-1 receptor therapies within current care pathways, including systemic, logistical, and cultural factors.

Apply strategies to integrate GLP-1 receptor therapies into patient care plans where clinically appropriate.

Evaluate opportunities to overcome institutional inertia and access limitations in order to optimize patient outcomes with these biologic innovations.

Donna H. Ryan, MD, FTOS, MABOM

Professor Emerita, Pennington Biomedical Research Center

Dr. Donna Ryan is Professor Emerita at Pennington Biomedical Research Center where she had a long career as clinician scientist. She now consults with companies making or developing medications, devices and lifestyle and medical weight management programs; speaks at continuing education programs; and works pro bono for not-for-profit obesity advocacy groups.

The Obesity Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Obesity Society designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ACCME Activity ID 203305180

Date of Release: November 1, 2025
Date of Termination: December 31, 2027

No commercial support was received for this activity.

Donna Ryan, MD, FTOS: Consulting Fee relationship with Boeringer Ingelheim (Pharmaceuticals); Consulting Fee, Stock Options relationship with Calibrate (Weight Management); Consulting Fee, Stock Options relationship with Epitomee (Medical Device); Consulting Fee and Advisor relationship with Wondr Health (Weight Management); Advisor relationship with Abbvie (Pharmaceuticals); Advisor relationship with Amgen (Pharmaceutical); Advisor relationship with Astra Zenica (Pharmaceutical); Advisor relationship with Biohaven (Pharmaceuticals); Advisor relationship with Carmot/Roche (Pharmaceuticals); Advisor relationship with Currax (Pharmaceuticals); Advisor and stock options relationship with Epitomee (Medical Device); Advisor relationship with Fractyl (Pharmaceuticals); Advisory, Speaker, Data monitoring (Pharmaceuticals); Advisor relationship with Pfizer. (Pharmaceuticals); Advisor relationship with Source Bio (Pharmaceuticals); Advisor relationship with Regeneron (Pharmaceuticals); Advisor relationship with Structure (Pharmaceuticals); Advisor relationship with Tenvie (Pharmaceuticals); Advisor relationship with Zealand (Biomedical); Consultant relationship with Nestle (Medical Food); Consultant relationship with eMed (Telehealth); Advisor and Data Monitoring Committee relationship with CinRX (Pharmaceuticals); former advisor ended more than 24 months ago; stock options relationship with Roman (Telehealth); Data Monitoring Committee relationship with Rhythm (Pharmaceuticals)

Monica Agarwal, MD, MEHP, FACE: No relevant financial relationships

No members of the TOS CME Oversight Committee, charged with the resolution of all relevant conflicts of interest, had any relevant financial relationships while serving on the committee.

1. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 2023;389:2221-2232.
2. Drucker DJ. GLP-1 physiology informs the pharmacotherapy of obesity. Mol Metab. 2022 Mar;57:101351.
3. Wong CK, McLean BA, Baggio LL, Koehler JA, Hammoud R, Rittig N, Yabut JM, Seeley RJ, Brown TJ, Drucker DJ. Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced inflammation. Cell Metab. 2024 Jan 2;36(1):130-143.e5.

4. Aseel Yaseen, Sharon W. Lahiri; Health Care Provider Prescribing Habits and Barriers to Use of New Type 2 Diabetes Medications: A Single-System Survey Study. Clin Diabetes 1 October 2023; 41 (4): 490–501. https://doi.org/10.2337/cd22-0100
5. Patrick P. Gleason, PharmD, BCPS, Benjamin Y. Urick, PharmD, PhD, Landon Z. Marshall, PharmD, PhD, Nicholas Friedlander, PharmD, Yang Qiu, MS, and R. Scott Leslie, MPH, PhD. Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes. Journal of Managed Care & Specialty Pharmacy, Volume 30, Number 8. https://doi.org/10.18553/jmcp.2024.23332